On April 21, 2026, TuHURA Biosciences, Inc. secured a $50 million revolving credit facility from Parkview Holdings, intended for clinical trials and development, with a maturity date of April 21, 2031. The loan has a 12% annual interest rate and includes specific covenants and potential profit-sharing provisions.